Masimo Corp. Stock
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | - | - | - | - | - | - | - |
| Haemonetics Corp. | 2.840% | 5.797% | 7.353% | - | 6.569% | - | - |
| Bio-Rad Labs Inc. A | -0.480% | 6.562% | 10.604% | 30.681% | 10.818% | -24.392% | -51.966% |
| CONMED Corp. | -2.590% | 4.918% | 28.000% | -10.698% | 9.714% | -64.112% | -67.179% |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


